ProCE Banner Activity

Key PTCL Studies Presented at ASH 2019

Clinical Thought
In this commentary, Barbara Pro, MD, highlights key studies on PTCL at the 2019 ASH annual meeting in Orlando.

Released: December 06, 2019

Expiration: December 04, 2020

No longer available for credit.

Share

Faculty

Barbara Pro

Barbara Pro, MD

Professor of Medical Oncology
Chief of Lymphoma Section
Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation
Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Seagen

Takeda Oncology

Faculty Disclosure

Primary Author

Barbara Pro, MD

Professor of Medical Oncology
Chief of Lymphoma Section
Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation
Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, Pennsylvania

Barbara Pro, MD, has disclosed that she has received consulting fees from ADC Therapeutics, Celgene, Kyowa, Portola, Seattle Genetics, and Takeda and funds for research support from Celgene, Seattle Genetics, and Takeda.